Expression of Bcl-2 in human breast cancer: Correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis

Pathology International

Volumn 47, Issue 11, 1997, Pages 757-762

  Hori, Masao ^a   Nogami, Tatsuya ^a   Itabashi, Masayuki ^a   Yoshimi, Fuyo ^a   Ono, Hisayuki ^a   Koizumi, Sumihiko ^a  

^a IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Apoptosis; Bcl 2; Hormone receptors; Human breast cancer; P53 oncoprotein

Indexed keywords

DNA; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; RNA;

APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DNA STRAND BREAKAGE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030692109     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1997.tb04453.x     Document Type: Article

References (24)

1. Tsujimoto Y, Cossman J, Jaffe E et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440-1443.
2. Crescenzi M, Seto M, Herzig GP et al. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc. Natl Acad. Sci. USA 1988; 85: 4869-4873.
3. Nathan B, Gusterson B, Jadayel D et al. Expression of BCL-2 in primary breast cancer and its correlation with tumor phenotype. Ann. Oncol. 1994; 5: 409-414.
4. Gasparini G, Barbareschi M, Doglioni C et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer Clin. Cancer Res. 1995; 1: 189-198.
5. Japanese Breast Cancer Society. General Rules For Clinical and Pathological Recording Of Breast Cancer, 11th edn. Kanehara Publications, Tokyo, 1992 (in Japanese).
6. Nishida M, Kasahara K, Oki A et al. Establishment of eighteen clones of Ishikawa cells. Hum. Cell 1996; 9: 109-116.
7. Brooks SC, Locke ER, Soule HD. Estrogen receptor in a human cell line (MCF-7) from breast carcinoma. J. Biol. Chem. 1973; 248: 6251-6253.
8. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl Acad. Sci. USA 1986; 83: 5214-5218.
9. Gavrieli Y, Shermen Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 1992; 119: 493-501.
10. Bhargava V, Kell DL, Rijn M et al. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am. J. Pathol. 1994; 145: 535-540.
11. Bargou RC, Daniel PT, Mapara MY et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-α expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer 1995; 60: 854-859.
12. Sabourin JC, Martin A, Baruch J et al. bcl-2 expression in normal breast tissue during the menstrual cycle. Int. J. Cancer 1994; 59: 1-6.
13. Pezzella F, Tse AGD, Cordell JL et al. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am. J. Pathol. 1990; 137: 225-232.
14. Kumaravel B, Arihiro K, Kaneko M et al. Expression of bcl-2 protein in breast carcinoma with correlation to expression of p53 protein and clinicopathological factors. Breast Cancer 1996; 3: 173-179.
15. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 1994; 145: 1191-1198.
16. Haldar S, Negrini M, Monne M et al. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994; 54: 2095-2097.
17. Lu QL, Abel P, Foster CS et al. bcl-2. Role in epithelial differentiation and oncogenesis. Hum. Pathol. 1996; 27: 102-110.
18. Leygue ER, Watson PH, Murphy LC. Estrogen receptor variants in normal human mammary tissue. J. Natl Cancer Inst. 1996; 88: 284-290.
19. Wang TTY, Phang JM. Effect of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 1995; 55: 2487-2489.
20. Tian Q, Streuli M, Saito H et al. A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell 1991; 67: 629-639.
21. Yin X-M, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369: 321-323.
22. Thor AD, Moore DH II, Edgerton SM et al. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J. Natl Cancer Inst. 1992; 84: 845-855.
23. Barnes DM, Dublin EA, Fisher CJ et al. Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? Hum. Pathol. 1993; 24: 469-476.
24. Pertschuk LP, Kim DS, Nayer K et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies: Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 1990; 66: 1663-1670.